Shanghai RAAS Blood Products Co., Ltd. (SHE:002252)

Market Cap	45.37B
Revenue (ttm)	7.95B
Net Income (ttm)	1.83B
Shares Out	6.60B
EPS (ttm)	0.28
PE Ratio	24.98
Forward PE	18.57
Dividend	0.07 (0.96%)
Ex-Dividend Date	Jul 14, 2025

Volume	38,901,145
Average Volume	32,250,921
Open	6.81
Previous Close	6.90
Day's Range	6.81 - 6.94
52-Week Range	6.50 - 7.83
Beta	0.38
RSI	58.33
Earnings Date	Oct 28, 2025

About HSBC Holdings

Shanghai RAAS Blood Products Co., Ltd. engages in the manufacture and sale of blood products in China. It offers human serum albumin, human intravenous immunoglobulin, human coagulation factor VIII, human prothrombin complex, human fibrinogen, human thrombin and human fibrin adhesive, human immunoglobulin, hepatitis B immunoglobulin, tetanus immunoglobulin, and rabies immunoglobulin products. The company was founded in 1988 and is based in Shanghai, China.

• Industry: Biotechnology
• Sector: Healthcare
• Founded: 1988
• Employees: 3,350
• Stock Exchange: Shenzhen Stock Exchange
• Ticker Symbol: 002252

Financial Performance

In 2024, SHE:002252's revenue was 8.18 billion, an increase of 2.67% compared to the previous year's 7.96 billion. Earnings were 2.19 billion, an increase of 23.25%.